<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Goserelin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Goserelin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Goserelin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11209" href="/d/html/11209.html" rel="external">see "Goserelin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F177201"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zoladex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867078"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zoladex;</li>
<li>Zoladex LA</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F177239"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Gonadotropin-Releasing Hormone Agonist;</li>
<li>
                        Gonadotropin Releasing Hormone Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F177204"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70f72d8d-3f95-478a-a281-8d0e7521cd98">Breast cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced: Pre- and perimenopausal patients:</b>
<b>SUBQ:</b> 3.6 mg every 28 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b505fa02-cbc2-4225-9c22-241e880d236d">Breast cancer, advanced, with endocrine-based combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced, with endocrine-based combination therapy (off-label use): Pre- and perimenopausal patients: SUBQ:</b> 3.6 mg every 28 days (in combination with palbociclib and fulvestrant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26030518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26030518'])">Ref</a></span>) or in combination with ribociclib and an aromatase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29804902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29804902'])">Ref</a></span>)).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1d1821f-d301-4a40-b5a3-265e22a8e61c">Breast cancer, early stage, premenopausal ovarian preservation during chemotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, early stage, </b>
<b>premenopausal ovarian preservation during chemotherapy (off-label use):</b>
<b>SUBQ:</b> 3.6 mg once every 28 days starting at least 1 to 2 weeks prior to the first chemotherapy dose; continue until within 2 weeks before or after the final chemotherapy dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21537042','lexi-content-ref-29718793','lexi-content-ref-28472240','lexi-content-ref-25738668','lexi-content-ref-30371800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21537042','lexi-content-ref-29718793','lexi-content-ref-28472240','lexi-content-ref-25738668','lexi-content-ref-30371800'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="25aa6c91-5d54-4157-81ab-7c2cfc67e73d">Breast cancer, premenopausal ovarian suppression during adjuvant endocrine therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, premenopausal ovarian suppression during adjuvant endocrine therapy (off-label use): SUBQ:</b> 3.6 mg every 28 days for ~5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26884586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26884586'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fce34157-4fc3-4c4d-85bd-5aa3075eeef2">Breast cancer in male patients, hormone receptor-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer in male patients, hormone receptor-positive (off-label use): Note: </b>Should be used in combination with an aromatase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adva</i>
<i>nced or metastatic disease:</i>
<b> SUBQ:</b> 3.6 mg once every 4 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25980944','lexi-content-ref-23722469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25980944','lexi-content-ref-23722469'])">Ref</a></span>). Endocrine therapy for males with advanced or metastatic, hormone receptor-positive, HER2-negative breast cancer may be sequenced as in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59fc39c4-8a49-4579-a8e7-37368444460f">Endometrial thinning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial thinning:</b>
<b>SUBQ:</b> 3.6 mg every 28 days for 1 or 2 doses prior to endometrial ablation. Perform surgery at 4 weeks (if administering 1 dose) or within 2 to 4 weeks (following administration of the second depot).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b>
<b>SUBQ:</b> 3.6 mg every 28 days for 6 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a3883d-4739-41b4-8a5b-e87da10a3c21">Hormone therapy for transgender females, adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hormone therapy for transgender females (assigned male at birth), adjunct (off-label use): SUBQ:</b> 3.6 mg every 4 weeks in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20625973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20625973'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13531fc0-f759-4ce8-adf1-0f2fb51f128a">Prostate cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b></p>
<p style="text-indent:-2em;margin-left:4em;">28-day implant: <b>SUBQ: </b>3.6 mg every 28 days.</p>
<p style="text-indent:-2em;margin-left:4em;">12-week implant: <b>SUBQ: </b>10.8 mg every 12 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aea6d974-c8ed-4acc-92bc-0b738b6758a2">Prostate cancer, stage B2 to C, in combination with an antiandrogen and radiotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, stage B2 to C, in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Combination 28-day/12-week implant: <b>SUBQ: </b>3.6 mg, followed in 28 days by 10.8 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">28-day implant (alternate dosing): <b>SUBQ: </b>3.6 mg; repeated every 28 days for a total of 4 doses.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990346"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50987714"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block dot drugH1Div" id="F56788027"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Bone mineral density loss: Institute preventative treatment if necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Bone pain worsening (temporary): Manage symptomatically.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular disease (signs/symptoms): Manage according to current clinical practice.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypercalcemia: Initiate appropriate management if hypercalcemia occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia: Manage hyperglycemia and/or diabetes as clinically appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">Pituitary apoplexy: Requires immediate medical attention.</p>
<p style="text-indent:-2em;margin-left:2em;">Tumor flare, cord compression, or urinary tract obstruction (in prostate cancer): Manage with standard treatment; consider orchiectomy for extreme cases.</p></div>
<div class="block doe drugH1Div" id="F177205"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Males: Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F177173"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (females: 21%; males: 1% to 5%), vasodilation (females: 57%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (females: 42%), diaphoresis (females: 16% to 45%; males: 6%), seborrhea (females: 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (females: 48% to 61%), hot flash (females: 70% to 96%; males: 60% to 62%), increased libido (females: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 11%), nausea (5% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast atrophy (females: 33%), breast hypertrophy (females: 18%), decrease in erectile frequency (18%), dyspareunia (females: 14%), genitourinary signs and symptoms (lower; males: 13%), pelvic symptoms (females: 18%), sexual disorder (males: 21%), vaginitis (75%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor flare</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (females: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (5% to 11%), depression (females: 54%; males: 1% to 5%), emotional lability (females: 60%), headache (females: 32% to 75%; males: 1% to 5%), insomnia (5% to 11%), pain (8% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (males: 1% to 5%), angina pectoris (males: 1% to 5%), cardiac arrhythmia (males: 1% to 5%), chest pain (1% to 5%), edema (5% to 7%), heart failure (males: 5%), hypertension (6%), palpitations (females: 1% to 5%), peripheral vascular disease (males: 1% to 5%), pulmonary embolism (males: 1% to 5%), tachycardia (females: 1% to 5%), varicose veins (males: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (females: 1% to 5%), ecchymoses (females: 1% to 5%), hair disease (females: 4%), pruritus (2%), skin discoloration (females: 1% to 5%), skin rash (6%), xeroderma (females: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (males: 1% to 5%), gynecomastia (males: 8%), hirsutism (females: 7%), hyperglycemia (males: 1% to 5%), weight gain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (5%), constipation (1% to 5%), diarrhea (1% to 5%), dyspepsia (females: 1% to 5%), flatulence (females: 1% to 5%), gastric ulcer (males: 1% to 5%), hematemesis (males: 1% to 5%), increased appetite (females: 2%), vomiting (4%), xerostomia (females: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder neoplasm (males: 1% to 5%), breast swelling (males: 1% to 5%), breast tenderness (males: 1% to 5%), dysmenorrhea (1% to 5%), hematuria (males: 1% to 5%), impotence (males: 1% to 5%), mastalgia (7%), pelvic pain (6% to 9%), urinary frequency (1% to 5%), urinary incontinence (males: 1% to 5%), urinary retention (males: 1% to 5%), urinary tract abnormality (males: 1% to 5%), urinary tract infection (1% to 5%), urinary tract obstruction (males: 1% to 5%), urination disorder (males: 1% to 5%), uterine hemorrhage (6%), vaginal hemorrhage (1% to 5%), vulvovaginitis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (males: 1% to 5%), hemorrhage (females: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (females: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (males: 1% to 5%), sepsis (males: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (females: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (females: 1% to 5%), anxiety (1% to 5%), cerebral ischemia (males: 1% to 5%), cerebrovascular accident (males: 1% to 5%), chills (males: 1% to 5%), dizziness (5% to 6%), drowsiness (females: 1% to 5%), fatigue (females: ≤5%), hypertonia (females: 1%), lethargy (≤8%), malaise (females: ≤5%), migraine (females: 7%), nervousness (females: 3% to 5%), paresthesia (1% to 5%), voice disorder (females: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (females: 1% to 5%), arthropathy (females: 1% to 5%), back pain (4% to 7%), gout (males: 1% to 5%), lower limb cramp (females: 2%), myalgia (females: 3%), ostealgia (males: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (females: 1% to 5%), dry eye syndrome (females: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (males: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (females: 1% to 5%), chronic obstructive pulmonary disease (males: 5%), cough (1% to 5%), dyspnea (males: 1% to 5%), epistaxis (females: 1% to 5%), flu-like symptoms (5%), pharyngitis (females: 5%), pneumonia (males: 1% to 5%), rhinitis (females: 1% to 5%), sinusitis (females: 1% to 5%), upper respiratory tract infection (males: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Decreased HDL cholesterol, increased HDL cholesterol, increased LDL cholesterol, increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis, hypotension, vascular injury</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (patients with bone metastases), hypovolemic shock, pituitary apoplexy, pituitary neoplasm (including adenoma)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ovarian cyst, ureteral obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bleeding at injection site, hematoma at injection site, pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Psychotic reaction, seizure, spinal cord compression, suicidal ideation, suicidal tendencies, transient ischemic attacks</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture, osteoporosis</p></div>
<div class="block coi drugH1Div" id="F177186"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to goserelin, gonadotropin-releasing hormone (GnRH), GnRH agonist analogues, or any component of the formulation; during pregnancy for the treatment of endometriosis or endometrial thinning.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Undiagnosed vaginal bleeding, pregnancy, breastfeeding.</p></div>
<div class="block war drugH1Div" id="F177170"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cervical resistance: Cervical resistance may be increased; use caution when dilating the cervix for endometrial ablation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased bone density: Decreased bone mineral density has been reported in females and may be irreversible; use caution if other risk factors are present.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Hypercalcemia has been reported in patients with prostate cancer and breast cancer with bone metastases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia: Hyperglycemia has been reported in patients with prostate cancer and may manifest as diabetes or worsening of preexisting diabetes (worsening glycemic control).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including acute anaphylactic reactions) and antibody formation may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection site injury: Injection site and vascular injury, including pain, hematoma, hemorrhage, and hemorrhagic shock (requiring blood transfusions or surgical intervention) have been reported with goserelin. Use extra caution when administering to patients with a low BMI and/or to patients receiving full dose anticoagulation. Use caution while injecting goserelin into the anterior abdominal wall (due to the proximity of underlying inferior epigastric artery and its branches). Inform patient to immediately report abdominal pain, abdominal distention, dyspnea, dizziness, hypotension, and/or altered level of consciousness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with gonadotropin-releasing hormone (GnRH) agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and, infrequently, cardiovascular collapse; immediate medical attention required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: Symptoms of emotional lability (eg, crying, irritability, anger, aggression, impatience) have been reported with GnRH agonists, including goserelin; monitor for the development or worsening of psychiatric symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric events: Depression (new or worsening), including rare reports of suicidal ideation and attempt, has been reported in women being treated with GnRH agonists, including goserelin. Consider referral to a mental health professional in patients with new or worsening depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor flare: Transient increases in serum testosterone (in patients with prostate cancer) and estrogen (in patients with breast cancer) may result in a worsening of disease signs and symptoms (tumor flare) during the first few weeks of treatment. Some patients experienced a temporary worsening of bone pain, which may be managed symptomatically. Spinal cord compression and urinary tract obstruction have been reported in patients with prostate cancer; symptoms include ureteral obstruction, weakness, and paresthesias in first few weeks of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Androgen deprivation therapy may increase the risk for cardiovascular disease (Levine 2010). An increased risk for myocardial infarction, sudden cardiac death, and stroke has been observed. Androgen deprivation therapy may cause prolongation of the QT/QTc interval; evaluate risk versus benefit in patients with congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients taking medication known to prolong the QT interval.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Body weight: A decreased AUC may be observed when using the 3-month implant in patients with obesity. Use extra care when administering to patients with a low BMI to avoid injection site injury.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Implant removal: If removal is necessary, implant may be located by ultrasound.</p></div>
<div class="block foc drugH1Div" id="F177180"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoladex: 3.6 mg (1 ea); 10.8 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F177166"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F177188"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Zoladex Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.6 mg (per each): $1,135.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10.8 mg (per each): $3,184.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867079"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoladex: 3.6 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoladex LA: 10.8 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F177183"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Administer implant by inserting needle into the anterior abdominal wall below the navel line at a 30- to 45-degree angle in a continuous motion until the protective sleeve touches the patient's skin; grasp barrel at the finger grip and fully depress plunger. Use caution while injecting goserelin into the anterior abdominal wall (due to the proximity of underlying inferior epigastric artery and its branches). Goserelin is an implant; therefore, do not attempt to eliminate air bubbles prior to injection (may displace implant). Do not attempt to aspirate prior to injection; if a large vessel is penetrated, blood will be visualized in the syringe chamber (if vessel is penetrated, withdraw needle and inject elsewhere with a new syringe). Do not penetrate into muscle or peritoneum. Implant may be detected by ultrasound if removal is required. Monitor for signs/symptoms of abdominal hemorrhage. Use extra care when administering goserelin to patients with a low BMI and/or to patients receiving full dose anticoagulation. Refer to product labeling for additional details.</p></div>
<div class="block hazard drugH1Div" id="F49132607"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F177181"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced (3.6 mg only):</b> Palliative treatment of advanced breast cancer in pre- and perimenopausal patients (estrogen and progesterone receptor values may help to predict if goserelin is likely to be beneficial).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial thinning (3.6 mg only):</b> Endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis (3.6 mg only):</b> Management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy (goserelin experience for endometriosis has been limited to patients ≥18 years of age treated for 6 months).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced (3.6 mg or 10.8 mg):</b> Palliative treatment of advanced carcinoma of the prostate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, stage B2 to C (3.6 mg or 10.8 mg):</b> Management of locally confined stage T2b to T4 (stage B2 to C) prostate cancer (in combination with an antiandrogen [eg, flutamide]); begin goserelin and antiandrogen therapy 8 weeks prior to initiating radiation therapy and continue during radiation therapy.</p></div>
<div class="block off-label drugH1Div" id="F26629444"><span class="drugH1">Use: Off-Label: Adult</span><p>Breast cancer, advanced, with endocrine-based combination therapy; Breast cancer, early stage, premenopausal ovarian preservation during chemotherapy; Breast cancer, premenopausal ovarian suppression during adjuvant endocrine therapy; Breast cancer in male patients, hormone receptor-positive; Hormone therapy for transgender females (assigned male at birth)</p></div>
<div class="block mst drugH1Div" id="F56381725"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (when treating endometriosis or endometrial thinning) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299420"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220698"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Flotufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of ADT on the performance of flotufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Androgen Deprivation Therapy Agents may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact of ADT on the performance of gallium Ga 68 PSMA-11 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Piflufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of ADT on the performance of piflufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307030"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">When used for endometriosis or endometrial thinning, patients who could become pregnant should not receive goserelin until pregnancy has been excluded. Nonhormonal contraception is recommended for premenopausal patients during therapy and for 12 weeks after therapy is discontinued. Although ovulation is usually inhibited and menstruation may stop, pregnancy prevention is not ensured during goserelin therapy. Changes in reproductive function may occur following chronic administration.</p>
<p style="text-indent:0em;margin-top:2em;">Goserelin may prevent premature ovarian failure when added to chemotherapy in patients with early stage hormone receptor negative breast cancer. In one study, patients followed for 5 years were less likely to experience ovarian failure and more likely to become pregnant than patients who did not receive goserelin in addition to their chemotherapy. The desire to become pregnant and the incidence of prior pregnancies was not considered in the analysis, and pregnancies occurred in some patients who were not attempting to conceive (Moore 2015; Moore 2019). Use of gonadotropin-releasing hormone (GnRH) agonists such as goserelin for preserving ovarian function and potentially maintaining future fertility may be considered for some premenopausal patients undergoing chemotherapy (ACOG 2018; ASCO [Oktay 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Goserelin may also cause erectile dysfunction and decreased libido. Intermittent therapy (if possible and if clinically appropriate) may improve quality of life in patients treated for prostate cancer (Semet 2017).</p></div>
<div class="block pri drugH1Div" id="F177189"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Goserelin induces hormonal changes, which increase the risk for fetal loss.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following inadvertent goserelin exposure during pregnancy are limited (Hill 2011; Ishizuka 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Use is contraindicated during pregnancy for the treatment of endometriosis or endometrial thinning. If used for the palliative treatment of breast cancer during pregnancy, the potential for increased fetal loss should be discussed with the patient.</p></div>
<div class="block brc drugH1Div" id="F9404689"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if goserelin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F9404926"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor blood glucose and HbA<sub>1c</sub> (periodically and as clinically necessary), bone mineral density, serum calcium, cholesterol/lipids. Monitor for signs/symptoms of abdominal hemorrhage (following injection), depression (especially in females), hypersensitivity reaction, and pituitary apoplexy (eg, sudden headache, vomiting, visual or mental status changes, and, infrequently, cardiovascular collapse).</p>
<p style="text-indent:-2em;margin-left:2em;">Breast cancer (ovarian suppression during adjuvant endocrine therapy; off-label use): Monitor for physiologic changes that may be indicative of ovarian function recovery (eg, resumption of menses, cyclical fluctuations in climacteric symptoms) (ASCO [Burstein 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">Endometriosis, endometrial thinning: Evaluate pregnancy status prior to use.</p>
<p style="text-indent:-2em;margin-left:2em;">Prostate cancer: Consider periodic ECG and electrolyte monitoring (correct electrolytes prior to treatment initiation). Monitor testosterone levels if desired clinical response is not observed, particularly in patients with obesity. Monitor for weakness, paresthesias, tumor flare, urinary tract obstruction, and spinal cord compression in first few weeks of therapy; monitor for signs/symptoms of cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Transgender hormone therapy (off-label use): Serum testosterone levels (goal &lt;50 ng/dL) every 3 months during the first year and then annually or biannually; serum luteinizing hormone, follicle-stimulating hormone, and prolactin levels at baseline and annually; routine cancer and laboratory screening as in non-transgender individuals for all tissues present (ES [Hembree 2017]; Mueller 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring for patients with prostate cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; baseline and serial ECGs are recommended in patients at risk of QTc prolongation during androgen deprivation therapy (ADT); estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually during ADT (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F177169"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Goserelin (a gonadotropin-releasing hormone [GnRH] analog) causes  an initial increase in luteinizing hormone (LH) and follicle stimulating hormone (FSH), chronic administration of goserelin results in a sustained suppression of pituitary gonadotropins. Serum testosterone falls to levels comparable to surgical castration. The exact mechanism of this effect is unknown, but may be related to changes in the control of LH or down-regulation of LH receptors.</p></div>
<div class="block phk drugH1Div" id="F177185"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset:</p>
<p style="text-indent:-2em;margin-left:4em;">Females: Estradiol suppression reaches postmenopausal levels within 3 weeks and FSH and LH are suppressed to follicular phase levels within 4 weeks of initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with prostate cancer: Testosterone suppression reaches castrate levels within 2 to 4 weeks after initiation.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Females: Estradiol, LH and FSH generally return to baseline levels within 12 weeks following the last monthly implant.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with prostate cancer: Testosterone levels maintained at castrate levels throughout the duration of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: SUBQ: Rapid and can be detected in serum in 30 to 60 minutes; 3.6 mg: released slowly in first 8 days, then rapid and continuous release for 28 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Male: 44.1 L; Female: 20.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~27%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic hydrolysis of the C-terminal amino acids.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: SUBQ: Male: 12 to 15 days, Female: 8 to 22 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;90%; 20% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51196153"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Sex: The total body Cl of goserelin was significantly (<i>P</i> &lt;0.05) greater (163.9 vs 110.5 L/min) in females compared with males.</p>
<p style="text-indent:-2em;margin-left:2em;">Body weight: A decline in AUC of approximately 1% to 2.5% was observed with a kg increase in body weight.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F177190"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zoladex | Zoladex la | Zoladex SafeSystem</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zoladex | Zoladex la</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Xanderla</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Zoladex</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Zoladex | Zoladex la</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30045213">
<a name="30045213"></a>American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 747: Gynecologic issues in children and adolescent cancer patients and survivors. <i>Obstet Gynecol</i>. 2018;132(2):e67-e77. doi:10.1097/AOG.0000000000002763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/30045213/pubmed" id="30045213" target="_blank">30045213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25199761">
<a name="25199761"></a>Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/25199761/pubmed" id="25199761" target="_blank">25199761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16545560">
<a name="16545560"></a>Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. <i>Eur J Cancer</i>. 2006; 42(7):895-904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/16545560/pubmed" id="16545560" target="_blank">16545560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26884586">
<a name="26884586"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. <i>J Clin Oncol</i>. 2016;34(14):1689-1701. doi:10.1200/JCO.2015.65.9573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/26884586/pubmed" id="26884586" target="_blank">26884586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30452337">
<a name="30452337"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update.<i> J Clin Oncol</i>. 2019;37(5):423-438. doi:10.1200/JCO.18.01160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/30452337/pubmed" id="30452337" target="_blank">30452337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25980944">
<a name="25980944"></a>Di Lauro L, Pizzuti L, Barba M, et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>J Hematol Oncol.</i> 2015;8:53. doi:10.1186/s13045-015-0147-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/25980944/pubmed" id="25980944" target="_blank">25980944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16320157">
<a name="16320157"></a>Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. <i>Exp Clin Endocrinol Diabetes</i>. 2005;113(10):586-592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/16320157/pubmed" id="16320157" target="_blank">16320157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21537042">
<a name="21537042"></a>Gerber B, von Minckwitz G, Stehle H, et al; German Breast Group Investigators. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. <i>J Clin Oncol</i>. 2011;29(17):2334-2341. doi:10.1200/JCO.2010.32.5704<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/21537042/pubmed" id="21537042" target="_blank">21537042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21900112">
<a name="21900112"></a>Griggs JJ, Somerfield MR, Anderson H, et al. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer [published correction appears in <i>J Clin Oncol</i>. 2012 Apr 20;30(12):1398]. <i>J Clin Oncol</i>. 2011;29(29):3939-3942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/21900112/pubmed" id="21900112" target="_blank">21900112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19244174">
<a name="19244174"></a>Hackshaw A, Baum M, Fornander T, et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. <i>J Natl Cancer Inst</i>. 2009; 101(5):341-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/19244174/pubmed" id="19244174" target="_blank">19244174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29320642">
<a name="29320642"></a>Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. <i>Endocr Pract</i>. 2017;23(12):1437. doi: 10.4158/1934-2403-23.12.1437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/29320642/pubmed" id="29320642" target="_blank">29320642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21541703">
<a name="21541703"></a>Hill N, Madarnas Y. Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature. <i>Breast Cancer Res Treat</i>. 2011;129(1):265-268. doi:10.1007/s10549-011-1542-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/21541703/pubmed" id="21541703" target="_blank">21541703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413638">
<a name="18413638"></a>Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. <i>J Clin Oncol</i>. 2008; 26(15):2497-2504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/18413638/pubmed" id="18413638" target="_blank">18413638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14679153">
<a name="14679153"></a>International Breast Cancer Study Group (IBCSG); Castiglione-Gertsch M, O'Neill A, Price KN, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. <i>J Natl Cancer Inst</i>. 2003;95(24):1833-1846. doi:10.1093/jnci/djg119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/14679153/pubmed" id="14679153" target="_blank">14679153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636905">
<a name="23636905"></a>Ishizuka S, Satou S. A case of delivery of healthy infant in breast cancer patient incidentally treated with goserelin acetate and tamoxifen during pregnancy. <i>Breast Cancer</i>. 2016;23(1):164-166. doi:10.1007/s12282-013-0469-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/23636905/pubmed" id="23636905" target="_blank">23636905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29718793">
<a name="29718793"></a>Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. <i>J Clin Oncol</i>. 2018;36(19):1981-1990. doi:10.1200/JCO.2018.78.0858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/29718793/pubmed" id="29718793" target="_blank">29718793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28472240">
<a name="28472240"></a>Leonard RCF, Adamson DJA, Bertelli G, et al; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute Trialists. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. <i>Ann Oncol</i>. 2017;28(8):1811-1816. doi:10.1093/annonc/mdx184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/28472240/pubmed" id="28472240" target="_blank">28472240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124128">
<a name="20124128"></a>Levine GN, D’Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. A science advisory from the American Heart Association, American Cancer Society, and American Urological Association. <i>Circulation</i>, 2010, 121(6):833-840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/20124128/pubmed" id="20124128" target="_blank">20124128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23715580">
<a name="23715580"></a>Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2013;31(19):2500-2510. Available at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.49.2678 Accessed September 29, 2014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/23715580/pubmed" id="23715580" target="_blank">23715580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25738668">
<a name="25738668"></a>Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. <i>N Engl J Med</i>. 2015;372(10):923-932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/25738668/pubmed" id="25738668" target="_blank">25738668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30371800">
<a name="30371800"></a>Moore HCF, Unger JM, Phillips KA, et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG Intergroup S0230. <i>J Natl Cancer Inst</i>. 2019;111(2):210-213. doi:10.1093/jnci/djy185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/30371800/pubmed" id="30371800" target="_blank">30371800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20625973">
<a name="20625973"></a>Mueller A, Zollver H, Kronawitter D, et al. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. <i>Exp Clin Endocrinol Diabetes</i>. 2011;119(2):95-100. doi: 10.1055/s-0030-1255074.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/20625973/pubmed" id="20625973" target="_blank">20625973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18172188">
<a name="18172188"></a>Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. <i>J Clin Oncol</i>. 2008; 26(4):585-591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/18172188/pubmed" id="18172188" target="_blank">18172188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10368200">
<a name="10368200"></a>Sarosdy MF, Schellhammer PF, Soloway MS, et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. <i>BJU Int</i>. 1999;83(7):801-806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/10368200/pubmed" id="10368200" target="_blank">10368200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28580882">
<a name="28580882"></a>Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. <i>J Clin Oncol.</i> 2017;35(25):2875-2884. doi:10.1200/JCO.2017.73.7585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/28580882/pubmed" id="28580882" target="_blank">28580882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29804902">
<a name="29804902"></a>Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor positive, advanced breast cancer (MONALEESA-7): a randomized phase 3 trial. <i>Lancet Oncol</i>. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/29804902/pubmed" id="29804902" target="_blank">29804902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26030518">
<a name="26030518"></a>Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. <i>N Engl J Med</i>. 2015;373(3):209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/ 26030518/pubmed" id=" 26030518" target="_blank"> 26030518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25850534">
<a name="25850534"></a>Zagouri F, Sergentanis TN, Azim HA Jr, et al. Aromatase inhibitors in male breast cancer: a pooled analysis. <i>Breast Cancer Res Treat</i>. 2015;151(1):141-147. doi:10.1007/s10549-015-3356-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/25850534/pubmed" id="25850534" target="_blank">25850534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23722469">
<a name="23722469"></a>Zagouri F, Sergentanis TN, Koutoulidis V, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. <i>Br J Cancer.</i> 2013;108(11):2259-2263. doi:10.1038/bjc.2013.255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/23722469/pubmed" id="23722469" target="_blank">23722469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TerSera.1">
<a name="TerSera.1"></a>Zoladex 3.6 mg (goserelin) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TerSera.2">
<a name="TerSera.2"></a>Zoladex 10.8 mg (goserelin) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AstraZeneca.1">
<a name="AstraZeneca.1"></a>Zoladex (goserelin) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AstraZeneca.2">
<a name="AstraZeneca.2"></a>Zoladex LA (goserelin) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; March 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8500 Version 208.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
